POST KALA-AZAR DERMAL LEISHMANIASIS
Clinical trials for POST KALA-AZAR DERMAL LEISHMANIASIS explained in plain language.
Never miss a new study
Get alerted when new POST KALA-AZAR DERMAL LEISHMANIASIS trials appear
Sign up with your email to follow new studies for POST KALA-AZAR DERMAL LEISHMANIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Common drug tested for mysterious skin disease linked to parasite outbreaks
Disease control CompletedThis early study tested whether oral ivermectin could safely treat PKDL, a skin disease that appears after recovery from kala-azar (visceral leishmaniasis). Researchers compared ivermectin taken for three months against the standard 12-week miltefosine treatment in 30 patients in…
Matched conditions: POST KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Common drug tested for stubborn skin disease
Disease control CompletedThis small, early study tested if the drug ivermectin, taken by mouth, is safe and can help treat Post Kala-Azar Dermal Leishmaniasis (PKDL). PKDL is a skin condition that can appear after someone recovers from kala-azar (visceral leishmaniasis). The study involved 10 participant…
Matched conditions: POST KALA-AZAR DERMAL LEISHMANIASIS
Phase: EARLY_PHASE1 • Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC